



IMPROVING  
THE ENTIRE RT WORKFLOW

# SGRT: GAME CHANGER


A safe workflow for non-coplanar  
radiation therapy in H&N cancer

THE **2024** ANNUAL MEETING  
OF THE SGRT COMMUNITY

M. Gonod<sup>1</sup> ([mgonod@cgfl.fr](mailto:mgonod@cgfl.fr)), C. Chevalier<sup>2</sup>, L. Marichy<sup>1</sup>,  
O. Lorenzo<sup>1</sup>, L. Aubignac<sup>1</sup>, D. Thibouw<sup>2</sup>, I. Bessières<sup>1</sup>

<sup>1</sup> Medical Physics department CGFL/Dijon/France

<sup>2</sup> Radiation Therapy department CGFL/Dijon/France

 **28 & 29 Nov 2024**

 **etc.venues** County Hall (London)





Ensemble, dépassons le cancer

- Increasing the complexity of treatment
  - Increase restrictivity of OAR dose constraints, proportion of SBRT and re-irradiation
  - ➔ Increasing beam configuration complexity
    - ➔ Multiplying treatment fields
    - ➔ Increase proportion of N-Cop treatments

Year	Activity distribution	Complexification	Number of detected « collisions » at Dry run
2021	Conformal: 44% IMRT/VMAT: 31% SBRT: 25%	-	11
2022	Conformal: 35% IMRT/VMAT: 29% SBRT: 35%	-	11
2023	Conformal: 14% IMRT/VMAT: 57% SBRT: 29%	+	30
2024	Conformal: ~1% IMRT/VMAT: ~69% SBRT: ~30%	++	

➔ Increased risk of unfeasible plans




- **Lung**: Kim, Sang-Tae (2020) DOI: 10.1259/bjr.20190596
- **Lung**: Ma, Min (2021) DOI: 10.1002/acm2.13197
- **Head & Neck**: Gayen, Sanjib (2020) DOI: 10.3857/roj.2020.00143
- **Head & Neck**: Woods, Kaley E (2022) DOI: 10.3390/cancers14040939
- **Mediastinal**: Rossi, Linda (2021) DOI: 10.3389/fonc.2021.619929
- **Breast**: Frengen, J (2023) DOI: 10.1080/0284186X.2023.2264488
- **SBRT**: Biau J (2022) DOI:10.1016/j.ctro.2022.11.007
- **SBRT**: Lincoln J (2023) DOI: 10.1088/1361-6560/ace23f
- **Multi**: Bertholet J (2023) doi.org/10.1002/mp.16899
- **Multi**: Loebner HA (2023) DOI:10.1002/mp.16533

- Secure N-Cop plans

- Schedule a Dry Run session
- RTT have to go in-room for couch rotation between fields
  - ➔ Machine time: *Dry Run ~ 20 min* || *Couch rotation by RTT ~ + 30 s / rotation*

- Sept 2023: **maprt**<sup>®</sup>



- 1 year feedback

- Sept 2023 – June 2024: All plans for all patients ~900 plans
  - 22 unfeasible treatment avoided even if the planner was sure of himself
  - ~ 50 plans: mapRT analysis before beam configuration
  - ~ 165 plans optimised with MapRT

- 6 remaining « unfeasible treatment »
  - 4: acquisition or export oversights
  - 1: CBCT collision
  - 1: too thin immobilisation device part

→ CBCT inserted in mapRT v1.2 June 2024  
 → Buffer = 3 cm (after evaluation – paper JACMP dec 24)

- May 2024 – Oct. 2024: 0 unfeasible plan
- No need to perform on-machine beam configuration tests during the planning step

Year	Activity distribution	Complexity	Number of detected « collisions » at Dry run
2021	Conformal: 44% IMRT/VMAT: 31% SBRT: 25%	–	11
2022	Conformal: 35% IMRT/VMAT: 29% SBRT: 35%	–	11
2023	Conformal: 14% IMRT/VMAT: 57% SBRT: 29%	+	30
2024	Conformal: ~1% IMRT/VMAT: ~69% SBRT: ~30%	++	

## Time consuming

- CT Daily QA < 5 min
- Surface acquisition at CT < 1 min
- Plan check calculation < 1min



- 1 year feedback
  - Confidence in collision avoidance map
    - Dry run ?
    - N-cop: In-room RTT for couch rotation ?
  
- What is the impact on "non-complex" treatments?
  - Search for the site with the greatest advantage of N-cop planning
    - Head & Neck
      - Trade-off OAR sparing / PTV coverage
    - Impact on DVH ?
    - Impact on expected toxicities ?
    - Impact on treatment duration ?

Year	Activity distribution	Complexity	Number of detected « collisions » at Dry run
2021	Conformal: 44% IMRT/VMAT: 31% SBRT: 25%	-	11
2022	Conformal: 35% IMRT/VMAT: 29% SBRT: 35%	-	11
2023	Conformal: 14% IMRT/VMAT: 57% SBRT: 29%	+	30
2024	Conformal: ~1% IMRT/VMAT: ~69% SBRT: ~30%	++	6 (Jan - May) 0 (June - Nov)

Treatment

Dry run  
Fields test

Treatment fractions

CBCT

Arc1

Arc2

Couch rotation → in-room


Arc3

Arc4

5


- Head & Neck: **Actual workflow**

### Treatment planning



**maprt®**  
 42 Non cop-orthogonal arcs

- Collision status
- Beam optimisation



→ Improved DVH  
**True ?**



### Treatment

**Dry run**  
Field tests

**MET et fractions**

CBCT  
 Arc1  
 Arc2  
 Couch rotation → RTT in-room  
 Arc3  
 Arc4

- Reference plans

- 2-3 Cop arcs
- RapidPlan (Varian) v17 – PO/AAA v17



- 10 patients with bilateral CTV
- Dose 66/70 Gy – SIB

- DVH evaluation according to local practices
- Same PTV coverage


- Evaluated plans

- 4 N-Cop partial arcs
- Manual optimisation – PO/AAA v17




- Influence on OAR ?
- Gains on DVH ?
- Gains on expected toxicities?
- Workflow duration

- DVH differences: PTV



D95% = -0.0 Gy  
 D105% = -0.4 Gy

- = N-Cop advantage




D95% = -0.0 Gy  
 D105% = -0.0 Gy


+ = Cop advantage




- DVH differences: Parotids, spinal cord



$D_{\text{mean}} = -1.8 \text{ Gy}$



$D_{\text{max}} = -7.3 \text{ Gy}$






$D_{\text{mean}} = -1.8 \text{ Gy}$

- = N-Cop advantage

+ = Cop advantage


- DVH differences: Oral cavity, Larynx, Mandible, Oesophagus




- = N-Cop advantage

+ = Cop advantage


- DVH differences: Pharyngeal constrictor, Submaxillary, Humeral head



$D_{max} = -0.7 \text{ Gy}$



$D_{mean\_R} = -2.1 \text{ Gy}$   
 $D_{mean\_L} = -3.1 \text{ Gy}$





$D_{5\%\_R} = -3.7 \text{ Gy}$   
 $D_{5\%\_L} = -5.9 \text{ Gy}$


- = N-Cop advantage

+ = Cop advantage


- DVH differences: Mediastinal volume



Organ	$D_{max}$ (Gy)	$D_{mean}$ (Gy)
Ant chamber (R)	+0.6	
Ant chamber (L)	+1.3	
Chiasma	+0.4	
Cochlea R	-1.7	+0.5
Cochlea L	+0.5	-0.3
Brainstem	-2.2	



Cop



N-Cop

- Toxicity differences
  - Gains on DVH ≠ gains on expected toxicities
  - Evaluation of toxicities rate:

→ Cop – N-cop

Organ	Number of patients	Toxicity
Cochlea (R)	-2	Hearing loss for 15% of patients
Larynx	-1	Œsophagitis Grade ≥2
Parotid (L)	-1	Xerostomia
Parotid (R)	-1	Xerostomia

- No negative results on N-cop plans

Review > [Int J Radiat Oncol Biol Phys.](#) 1991 May 15;21(1):109-22.  
 doi: 10.1016/0360-3016(91)90171-y.

## Tolerance of normal tissue to therapeutic irradiation

B Emami <sup>1</sup>, J Lyman, A Brown, L Coia, M Goitein, J E Munzenrider, B Shank, L J Solin, M Wesson

Affiliations + expand

PMID: 2032882 DOI: [10.1016/0360-3016\(91\)90171-y](#)


Emami, B. (1991). Tolerance of normal tissue to therapeutic irradiation. *IJROPB* doi.org/10.1016/0360-3016(91)90171-Y

Emami, B. (2013). Tolerance of normal tissue to therapeutic radiation. *Reports of radiotherapy and Oncology*, 1(1), 123-7.



- Workflow duration


- Treatment duration



- Cop= (270 ± 36)s
  - N-Cop= (371 ± 9)s
  - N-Cop with MapRT= (319 ± 9)s
- Annotations: A bracket between N-Cop and N-Cop with MapRT is labeled '+101 s'. A bracket between Cop and N-Cop with MapRT is labeled '+49 s'.

- For 35 N-Cop MapRT fractions: 35x49 = +1715 s
- Dry run MapRT removable: - 1431 s
- For 35 fractions: + 284 s (< 5 min) / patient

- Dry run duration



- Dry Run N-Cop = (24 ± 8.5) min (1431 ± 508)s
- Dry Run N-Cop with MapRT= (0 ± 0) min (0 ± 0)s

- Duration < +5 min / patient treatment
- Improvement on DVH
- Improvement on toxicities rate
- Only ten patients

- Practice changes
  - RTT & RO adoption  
(Dry run / rotations out of the bunker)
  - O-ring machine and couch rotation ?

## Treatment planning




**maprt<sup>®</sup>**

4 partial N-cop arcs

- Collision status
- Beam optimisation

OK



→ HDV improved

OK



## Treatment

Dry run

Fields test

To discuss with RTT & RO


**MET et fractions**

CBCT

- Arc1
- Arc2
- Arc3
- Arc4

Patient monitoring  
 Open masks  
 → RTT in room

To discuss with RTT & RO



## Dynamic Trajectory RadioTherapy (DTRT)

**Dosimetrically motivated beam-angle optimization for non-coplanar arc radiotherapy with and without dynamic collimator rotation**

MEDICAL PHYSICS

Jenny Bertholet<sup>1</sup> | Chengchen Zhu<sup>1</sup> | Gian Guyer<sup>1</sup> | Silvan Mueller<sup>1</sup> | Werner Volken<sup>1</sup> | Paul-Henry Mackeprang<sup>1</sup> | Hannes A. Loebner<sup>1</sup> | Marco F. M. Stampanoni<sup>2</sup> | Daniel M. Aebersold<sup>1</sup> | Michael K. Fix<sup>1</sup> | Peter Manser<sup>1</sup>

*Phys. Med. Biol.* 69 (2024) 185009

A dosimetrically motivated pathfinding approach for non-isocentric dynamic trajectory radiotherapy


Gian Guyer<sup>1</sup> | Jenny Bertholet<sup>1</sup> | Silvan Mueller<sup>1</sup> | Chengchen Zhu, Werner Volken, Daniel M Aebersold, Peter Manser and Michael K Fix<sup>1</sup>

MEDICAL PHYSICS

**Dosimetric optimization for dynamic mixed beam arc therapy (DYMBARC)** DOI: 10.1002/mp.17467

Received: 19 April 2024 | Revised: 24 August 2024 | Accepted: 30 August 2024

Chengchen Zhu<sup>1</sup> | Gian Guyer<sup>1</sup> | Jenny Bertholet<sup>1</sup> | Silvan Mueller<sup>1</sup> | Hannes A. Loebner<sup>1</sup> | Werner Volken<sup>1</sup> | Julius Arnold<sup>2</sup> | Daniel M. Aebersold<sup>1</sup> | Marco F. M. Stampanoni<sup>3</sup> | Michael K. Fix<sup>1</sup> | Peter Manser<sup>1</sup>



**Technical note: Feasibility of gating for dynamic trajectory radiotherapy – Mechanical accuracy and dosimetric performance** MEDICAL PHYSICS


Accepted: 23 May 2023

Hannes A. Loebner<sup>1</sup> | Daniel Frauchiger<sup>1</sup> | Silvan Mueller<sup>1</sup> | Gian Guyer<sup>1</sup> | Paul-Henry Mackeprang<sup>1</sup> | Marco F. M. Stampanoni<sup>2</sup> | Michael K. Fix<sup>1</sup> | Peter Manser<sup>1</sup> | Jenny Bertholet<sup>1</sup>



**Impact of the gradient in gantry-table rotation on dynamic trajectory radiotherapy plan quality** MEDICAL PHYSICS

Accepted: 10 September 2023

Hannes A. Loebner<sup>1</sup> | Silvan Mueller<sup>1</sup> | Werner Volken<sup>1</sup> | Philipp Wallimann<sup>1</sup> | Daniel M. Aebersold<sup>1</sup> | Marco F. M. Stampanoni<sup>2</sup> | Michael K. Fix<sup>1</sup> | Peter Manser<sup>1</sup>




**FIGURE 1** DTRT trajectories (a), VMAT arcs (b) and motion phantom with DTRT trajectories (c) for the lung cancer case. The PTV is shown in red, lungs in blue, spinal cord in yellow, oesophagus in green, heart in white and the body surface in translucent grey. The red bands indicate the beam incidences of the DTRT and VMAT plan respectively.







## Dynamic Trajectory RadioTherapy (DTRT)



**FIGURE 2** DVHs for the head and neck cases (1, top and 2, bottom). The inserts show a coronal view of the colli-DTRT dose distribution (color scale: 5%–109% of the prescription dose).



**FIGURE 5** For case 4 (esophagus), score map at the first optimization and the last trimming step (2nd trimming) for colli-DTRT (top left) and NC-VMAT (top right) and the DVHs for all plans (bottom). The insert in the DVH shows a coronal view of the colli-DTRT dose distribution (color scale: 5%–109% of the prescription dose).



**FIGURE 6** DVHs for case 5 (lung, left) and case 6 (breast, right). The inserts show a coronal view of the colli-DTRT dose distribution (color scale: 5%–109% of the prescription dose).



IMPROVING  
THE ENTIRE RT WORKFLOW

# SGRT: GAME CHANGER


A safe workflow for non-coplanar  
radiation therapy in H&N cancer

THE **2024** ANNUAL MEETING  
OF THE SGRT COMMUNITY

M. Gonod<sup>1</sup> ([mgonod@cgfl.fr](mailto:mgonod@cgfl.fr)), C. Chevalier<sup>2</sup>, L. Marichy<sup>1</sup>,  
O. Lorenzo<sup>1</sup>, L. Aubignac<sup>1</sup>, D. Thibouw<sup>2</sup>, I. Bessières<sup>1</sup>

<sup>1</sup> Medical Physics department CGFL/Dijon/France

<sup>2</sup> Radiation Therapy department CGFL/Dijon/France

 **28 & 29 Nov 2024**

 **etc.venues** County Hall (London)



Ensemble, dépassons le cancer